Status:
COMPLETED
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
Lead Sponsor:
Sangamo Therapeutics
Collaborating Sponsors:
Alzheimer's Disease Cooperative Study (ADCS)
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain ...
Eligibility Criteria
Inclusion
- Diagnosis of mild to moderate Alzheimer's disease
- Approved medications for Alzheimer's disease may be taken if the dose has been stable for 3 months
- A study partner who can attend all study visits
- Good general health
- Medically able to undergo neurosurgery
Exclusion
- Significant neurological disease other than Alzheimer's disease
- Significant depression or other psychiatric disorder
- Unstable medical conditions
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2015
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00876863
Start Date
November 1 2008
End Date
August 13 2015
Last Update
December 21 2020
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35294
2
University of California, Los Angeles
Los Angeles, California, United States, 90095
3
University of California, San Diego
San Diego, California, United States, 92037
4
Georgetown University
Washington D.C., District of Columbia, United States, 20007